Ozempic has become one of the most searched medicine names in India over the past two years. That search volume is not coming from people with diabetes — although Ozempic is a diabetes medicine and that is what it is approved for. It is coming from people who have read
When a urologist or oncologist recommends Zoladex for prostate cancer, the word that tends to echo in the patient’s mind — and in the minds of their family — is the word they did not hear. The doctor explained what Zoladex does. They explained how it works, what to expect,
Walk into any oncology department at a major Indian hospital and you will find medicines from Germany, the United States, Switzerland, Japan, and the United Kingdom sitting alongside domestically manufactured generics. For most patients and their families, this raises a perfectly reasonable question: why is this medicine coming from abroad?
For decades, treating Alzheimer’s disease in India meant managing symptoms. Medications like rivastigmine and donepezil could slow cognitive decline for a period, but nothing available in the Indian market could actually target the disease process itself — the accumulating amyloid plaques in the brain that are understood to drive the
Two programs. Two very different purposes. And yet, for patients and families navigating serious illness in India, the terms Named Patient Program and Patient Assistance Program come up in the same conversations, recommended by the same doctors, and processed through the same hospital pharmacy counters — which is exactly why
Nobody in hospital procurement sets out to source from the wrong distributor. It usually starts with a budget conversation, a vendor offering a price that seems too good to ignore, or a time-pressured order where the usual channel isn’t available. The decision gets made quickly, the medicine arrives, and for
Trodelvy has become an increasingly requested medicine among Indian oncology centres treating triple-negative breast cancer, a subtype known for its aggressive course and historically limited treatment options. As demand for this antibody-drug conjugate grows, hospital procurement teams and pharmacies are asking more practical questions — less about the science, which
Denosumab has become one of the most widely supplied biologics in India for bone health management, spanning two very different clinical worlds — osteoporosis prevention and cancer-related bone protection. For hospitals, pharmacies, and procurement teams, the practical challenge is rarely about treatment decisions, which always rest with the prescribing physician
Goserelin, sold under the brand name Zoladex, has been a cornerstone of hormone therapy for more than three decades, and it remains one of the most consistently prescribed LHRH agonists across Indian oncology and gynaecology practices in 2026. Despite how established the molecule is, hospital pharmacists and procurement teams still
In May 2026, Delhi Police busted a counterfeit medicine racket worth nearly Rs 10 crore — four people arrested for manufacturing and supplying fake life-saving drugs for cancer and liver disease. Fake medicines, packaging equipment, forged labels — all recovered from an operation supplying hospitals across multiple states. Weeks earlier
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by
For most of the past two decades, Indian men diagnosed with advanced prostate cancer had a fairly narrow set of treatment options — hormone therapy, chemotherapy if the cancer progressed, and more recently oral targeted medicines like Enzalutamide (Glenza) and Abiraterone (Abirapro). These are genuinely effective medicines, but they work
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication
India’s diabetes and obesity treatment landscape changed dramatically in March 2026. Novo Nordisk’s core Indian patent for semaglutide expired on March 20, 2026 — within hours, a wave of Indian pharmaceutical companies launched their own versions at dramatically lower prices. Branded Ozempic costs ₹8,800–₹11,175 per month in India, while the
When hospitals, clinics, and pharmacies look for a medicine supplier, the most important factor is trust. Counterfeit or substandard medicines are a serious concern in India — and choosing the wrong supplier can put patients at risk. At A.K. Pharma, we understand this responsibility. As a licensed medicine wholesaler in
